Sugi Predict

Sugi Predict / Compounds / SCHEMBL2249309

SCHEMBL2249309

SCHEMBL2249309

Nc1ccc(-c2nc3ccccc3o2)c(O)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 10/20 0.63
▸ RAB9A P51151 10/20 0.63
▸ KDM6B O15054 1/20 0.61
▸ KDM6A O15550 1/20 0.61
▸ MEN1 O00255 5/20 0.59
▸ KMT2A Q03164 5/20 0.59
▸ ATM Q13315 1/20 0.59
▸ TOP2A P11388 1/20 0.58
▸ MAPT P10636 10/20 0.55
▸ SMN1; SMN2 Q16637 8/20 0.55
▸ TP53 P04637 7/20 0.55
▸ KDM4E B2RXH2 6/20 0.55
▸ HSD17B10 Q99714 4/20 0.55
▸ TSHR P16473 1/20 0.55
▸ ESR1 P03372 3/20 0.54
▸ ESR2 Q92731 3/20 0.54
▸ ALDH1A1 P00352 6/20 0.54
▸ HPGD P15428 4/20 0.54
▸ PTGS2 P35354 1/20 0.53
▸ PKM P14618 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2248620 0.89 KDM6B (0.73) NPC1RAB9AKDM6BKDM6AMEN1
SCHEMBL31631314 0.89 KDM6B (0.73) NPC1RAB9AKDM6BKDM6AMEN1
SCHEMBL13281919 0.87 NPC1 (0.63) NPC1RAB9AKDM6BKDM6AMEN1
SCHEMBL20503689 0.87 ESR1 (0.66) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL31410713 0.87 ESR1 (0.66) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL2245127 0.87 ESR1 (0.66) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL2243598 0.84 MAPT (0.71) NPC1RAB9AKDM6BKDM6AMEN1
SCHEMBL17654013 0.84 KDM6B (0.79) NPC1RAB9AKDM6BKDM6AMEN1
SCHEMBL30900831 0.84 KDM6B (0.79) NPC1RAB9AKDM6BKDM6AMEN1
SCHEMBL1550348 0.83 TOP2A (0.79) NPC1RAB9AKDM6BKDM6AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103467410-B A kind of acetate fluorescent probe compounds and application thereof DALIAN UNIVERSITY (CN) 2016-03-30 — — CN claimed
CN-102925136-B Zn<2+> ratiometric fluorescent probe compound and preparation method and use thereof UNIV DALIAN 2014-12-24 — — CN claimed
CN-103467410-A Fluorescent probe compound used for detection of acetate, and applications thereof UNIV DALIAN 2013-12-25 — — CN claimed
CN-102925136-A Zn<2+> ratiometric fluorescent probe compound and preparation method and use thereof UNIV DALIAN 2013-02-13 — — CN claimed
US-20230329100-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2023-10-12 — — US disclosed
CN-109970750-A A kind of detection various metals ion rhodamine probe and its preparation and application 东华大学 2019-07-05 — — CN disclosed
EP-3251694-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit (Oxford) Limited (GB) 2017-12-06 — — EP disclosed
CN-103467410-B A kind of acetate fluorescent probe compounds and application thereof DALIAN UNIVERSITY (CN) 2016-03-30 — — CN disclosed
CN-102925136-B Zn<2+> ratiometric fluorescent probe compound and preparation method and use thereof UNIV DALIAN 2014-12-24 — — CN disclosed
US-20140018320-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2014-01-16 — — US disclosed
US-20140011782-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2014-01-09 — — US disclosed
CN-103467410-A Fluorescent probe compound used for detection of acetate, and applications thereof UNIV DALIAN 2013-12-25 — — CN disclosed
CN-102925136-A Zn<2+> ratiometric fluorescent probe compound and preparation method and use thereof UNIV DALIAN 2013-02-13 — — CN disclosed
CN-101420950-B Treatment of duchenne muscular dystrophy SUMMIT CORP PLC 2012-04-18 — — CN disclosed
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy SUMMIT (OXFORD) LIMITED (GB) 2011-08-11 — — US disclosed
CN-101678107-A Pharmaceutical composition for treating Duchenne muscular dystrophy SUMMIT CORP PLC 2010-03-24 — — CN disclosed
CN-101420950-A Treatment of Duchenne muscular dystrophy SUMMIT CORP PLC (GB) 2009-04-29 — — CN disclosed
US-20090075938-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT (OXFORD) LIMITED (GB) 2009-03-19 — — US disclosed
EP-1986633-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit Corporation Plc (GB) 2008-11-05 — — EP disclosed
WO-2007091106-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2007-08-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230329100-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME SAT1, SLC1A2, SLC18A1 NPC1 3257/4885RAB9A 2664/4885KDM6B 1748/4885
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy PYGM, CPT1B, GYS1 NPC1 2477/4885RAB9A 3748/4885KDM6B 3100/4885
US-20140011782-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY PYGM, CPT1B, GYS1 NPC1 2477/4885RAB9A 3748/4885KDM6B 3100/4885
US-20140018320-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY NR0B1, NR0B2, NR3C1 NPC1 3637/4885RAB9A 4325/4885KDM6B 1737/4885
US-20090075938-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY NR0B1, NR0B2, NR3C1 NPC1 3637/4885RAB9A 4325/4885KDM6B 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.